Literature DB >> 9852249

The role of the soluble p53 antigen and its autoantibodies as markers for diagnosis of colon cancer: a comparative study.

B Sandler1, P Smirnoff, A Shani, E Idelevich, R Pfefferman, B Davidovich, R Zusman, I Zusman.   

Abstract

The role of various serological tumor markers, p53 soluble antigen and its autoantibodies, was evaluated for the detection of colon cancer in humans. An HPLC technique was used to measure serum levels of both forms of p53 protein after their partial isolation on gel fiberglass affinity chromatography columns. Tumor-associated proteins (TAP) in the form of either antigens or autoantibodies were about 4% of the total protein isolated from the serum of colon cancer patients. The absolute amount of each of the two types of TAP was also similar: 14.69 2.88 and 18.29 3.85 mg ml-1, respectively. The amount of p53 autoantibodies was higher than those of p53 antigen, but the difference was not significant: 9.35 3.48 and 6. 19 3.87 mg/ml, respectively (p>0.05). A good correlation was found between the total amount of tumor-associated antigens (TAA) and the amount of p53 antigen (r=0.69), total amount of IgG and the amount of p53 autoantibodies (r=0.46), and between both forms of p53 protein (r=0.46). A high coefficient of regression was found between the total amount of TAA and the amount of p53 antigen (b=2.4). Relationships between Duke's stage in colon cancer and the serum levels of p53 protein were weak: 0.33 and -0.32 for p53 antigen and its autoantibodies, respectively. Serum determination of p53 autoantibodies has no advantage over the determination of p53 antigen. Both forms of p53 protein can be isolated with extremely high accuracy for the pathological diagnosis of cancer (87-93%). Specificity of the method was proved using of commercial p53 PAb OD1: the GFG columns with this antibody were able to isolate the same proteins which were isolated by GFG columns with anti-p53 IgG. Moreover, the isolation of p53 protein was performed with higher effectiveness using the GFG columns with entrapped anti-p53 IgG than those columns with commercial DO1 PAb.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852249     DOI: 10.3892/ijmm.1.2.453

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  2 in total

1.  P53 autoantibodies in 1006 patients followed up for breast cancer.

Authors:  S Metcalfe; T K Wheeler; S Picken; S Negus
Journal:  Breast Cancer Res       Date:  2000-08-21       Impact factor: 6.466

2.  Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients.

Authors:  Ratchada Cressey; Saranya Pimpa; Busyamas Chewaskulyong; Nirush Lertprasertsuke; Somchareon Saeteng; Chatchai Tayapiwatana; Watchara Kasinrerk
Journal:  BMC Biotechnol       Date:  2008-02-20       Impact factor: 2.563

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.